Adaptive Biotechnologies Corp — fact timeline

Adaptive Biotechnologies Corp updated its full year 2026 guidance (raised).

“Raising full year 2026 MRD revenue guidance to a new range of $260 million to $270 million, implying annual growth of 22% to 27%.”

Adaptive Biotechnologies Corp reported the quarter ended March 31, 2026 results: revenue $70.9 million, net income $20.0 million.

“First Quarter 2026 Financial Results Revenue was $70.9 million for the quarter ended March 31, 2026, representing a 35% increase from the first quarter in the prior year. Excluding revenue recognized under the Genentech Agreement, which did not generate revenue in the quarter ended March 31, 2026, revenue for the current quarter increased 45% from the first quarter in the prior year. MRD revenue was $67.1 million for the quarter, representing a 53% increase from the first quarter in the prior year. Immune Medicine revenue was $3.8 million for the quarter, representing a 57% decrease from the first quarter in the prior year. Excluding revenue from the Genentech Agreement, Immune Medicine revenue for the quarter ended March 31, 2026 decreased 26% from the first quarter in the prior year. Operating expenses for the first quarter of 2026 were $90.1 million, compared to $82.0 million in the first quarter of the prior year, representing an increase of 10%. Interest and other income, net was”

Adaptive Biotechnologies Corp updated its full year 2024 guidance (lowered).

“Adaptive Biotechnologies expects full year revenue for the MRD business to be between $135 million and $140 million, updated from the previous range between $130 million and $140 million.”

Adaptive Biotechnologies Corp reported quarter ended March 31, 2024 results: revenue $41.9 million, net income $47.5 million loss.

“First Quarter 2024 Financial Results Revenue was $41.9 million for the quarter ended March 31, 2024, representing an 11% increase from the first quarter in the prior year. MRD revenue was $32.6 million for the quarter, representing a 52% increase from the first quarter in the prior year. Immune Medicine revenue was $9.2 million for the quarter, representing a 43% decrease from the first quarter in the prior year. Operating expenses were $90.6 million for the first quarter of 2024, compared to $94.8 million in the first quarter of the prior year, representing a decrease of 4%. MRD operating expenses were $59.9 million for the quarter, representing a 7% increase from the first quarter in the prior year. Immune Medicine operating expenses were $23.8 million for the quarter, representing a 25% decrease from the first quarter in the prior year. Interest and other income, net was $4.2 million for the first quarter of 2024, compared to $3.0 million in the first quarter of the prior year. Inte”

Kyle Piskel was appointed as Chief Financial Officer at Adaptive Biotechnologies Corp.

“As previously announced, Adaptive Biotechnologies Corporation (the “ Company ”) appointed Kyle Piskel, the Company’s Principal Accounting Officer, to serve as its Chief Financial Officer effective April 8, 2024.”

Adaptive Biotechnologies Corp reported first quarter ended March 31, 2024 results: revenue approximately $41 to $43 million.

“process and outcome of the strategic review during the conference call this afternoon. First Quarter 2024 Preliminary Unaudited Revenue Results • Total revenue of approximately $41 to $43 million for the first quarter of 2024, an increase of approximately 12% compared to the first quarter of 2023. • MRD revenue of approximately $31 to $32 million for the”

Kyle Piskel was appointed as Chief Financial Officer at Adaptive Biotechnologies Corp.

“Kyle Piskel, who has been with Company for 8 years and is currently its Principal Accounting Officer will serve as the Chief Financial Officer starting on April 8, 2024.”

Tycho Peterson resigned as Chief Financial Officer at Adaptive Biotechnologies Corp.

“On April 1, 2024, the Chief Financial Officer of Adaptive Biotechnologies Corporation (the “ Company ”) Tycho Peterson submitted his resignation.”

Adaptive Biotechnologies Corp reported fiscal year 2024 results: revenue between $130 million and $140 million. Guidance initiated.

“2024 Financial Guidance Adaptive Biotechnologies expects full year revenue for the MRD business to be between $130 million and $140 million. No revenue guidance is provided for the Immune Medicine business. We expect full year operating expenses, including cost of revenue, to be between $360 million and $370 million.”

Adaptive Biotechnologies Corp reported full year ended December 31, 2023 results: revenue $170.3 million, net income Net loss was $225.3 million.

“Revenue was $170.3 million for the year ended December 31, 2023, representing an 8% decrease from the prior year. MRD revenue was $102.7 million in 2023, representing an 18% increase from the prior year. Immune Medicine revenue was $67.5 million in 2023, representing a 31% decrease from 2022. Operating expenses for 2023, which include a $25.4 million lease impairment charge, were $397.3 million, compared to $385.5 million for 2022, representing an increase of 3%. Excluding the impact of the lease impairment charge, operating expenses for 2023 decreased 4% compared to the prior year. Interest and other income, net was $15.5 million in 2023, compared to $4.1 million in 2022. Interest expense from our revenue interest purchase agreement was $13.8 million in 2023, compared to $4.2 million in 2022. Net loss was $225.3 million in 2023, compared to $200.4 million in 2022. Adjusted EBITDA (non-GAAP) was a loss of $116.4 million for 2023, compared to a loss of $121.6 million in the prior year.”

Adaptive Biotechnologies Corp reported fourth quarter ended December 31, 2023 results: revenue $45.8 million, net income Net loss was $69.5 million.

“Revenue was $45.8 million for the quarter ended December 31, 2023, representing a 17% decrease from the fourth quarter in the prior year. MRD revenue was $30.8 million for the quarter, representing a 9% increase from the fourth quarter in the prior year. Immune Medicine revenue was $15.0 million for the quarter, representing a 45% decrease from the fourth quarter in the prior year. Operating expenses, which include a $25.4 million lease impairment charge, were $116.9 million for the fourth quarter of 2023, compared to $94.4 million in the fourth quarter of the prior year, representing an increase of 24%. Excluding the impact of the lease impairment charge, operating expenses for the fourth quarter of 2023 decreased 3% compared to the fourth quarter of the prior year. Interest and other income, net was $4.6 million for the fourth quarter of 2023, compared to $2.6 million in the fourth quarter of the prior year. Interest expense from our revenue interest purchase agreement was $3.0 milli”